AstraZeneca divestment of Movantik to RedHill Biopharma completed
2 April 2020 07:00 BST AstraZeneca divestment of Movantik to RedHill Biopharma completed AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo,